Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2012

View Archived Issues

Interim results reported from phase I/IIa ensituximab trial

PG-545 is active in several models of pancreatic cancer

GlaxoSmithKline scientists describe synthesis and preclinical testing of epelsiban

Biomarker of biliary tract carcinomas identified

Boehringer Ingelheim discloses novel 11-beta-HSD1 inhibitors

New free fatty acid FFA1 receptor agonists patented by Sanofi

Sanofi presents new casein kinase I inhibitors

La Jolla Pharmaceutical acquires rights to first-in-class galectin-3 inhibitor

Scientists at Roche prepare new GlyT-1 inhibitors

Sosei and Ceolia Pharma sign technical alliance agreement

Seikagaku launches phase II SI-614 study

FDA authorizes marketing of Quest Diagnostics test and label change for Tysabri

Chemotherapy combined with radiation shows promise in oligodendroglioma subtype

New serine/threonine-protein kinase B-raf inhibitors synthesized by Novartis

Italian company patents new muscarinic acetylcholine M3 receptor antagonists

ImmunoCellular Therapeutics provides update on phase III ICT-107 study

Treatment begins in Europe's first clinical study of hESC-derived cell therapy

Leeds University study reveals potential biomarker to monitor GIST progression

FDA extends PDUFA date for Adasuve NDA

Trius Therapeutics earns milestone payment from tedizolid collaboration

CHMP recommends updating Glivec label in Europe

Santhera regains fipamezole rights

BioAlliance Pharma advances its AMEP biotherapy

FDA approves subcutaneous Velcade

Medicure gives update on drug candidate for tardive dyskinesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...